Mirati Therapeutics (NASDAQ:MRTX) Raised to Sell at StockNews.com

Mirati Therapeutics (NASDAQ:MRTX – Get Rating) was upgraded by StockNews.com to a “sell” rating in a research report issued to clients and investors on Thursday.

A number of other research firms have also recently commented on MRTX. Bank of America raised shares of Mirati Therapeutics from an “underperform” rating to a “neutral” rating and lowered their price target for the stock from $171.00 to $141.00 in a report on Tuesday, February 1st. Morgan Stanley lowered their price target on shares of Mirati Therapeutics from $150.00 to $140.00 and set an “equal weight” rating on the stock in a report on Tuesday, March 1st. BMO Capital Markets lowered their price target on shares of Mirati Therapeutics from $187.00 to $130.00 in a report on Tuesday, March 1st. Oppenheimer lowered their price target on shares of Mirati Therapeutics from $175.00 to $155.00 in a report on Friday, February 18th. Finally, SVB Leerink reaffirmed an “outperform” rating on shares of Mirati Therapeutics in a report on Tuesday, February 8th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $173.27.

Shares of NASDAQ MRTX opened at $52.14 on Thursday. Mirati Therapeutics has a twelve month low of $51.69 and a twelve month high of $195.99. The stock’s 50 day moving average price is $76.74 and its 200-day moving average price is $112.56. The company has a market capitalization of $2.90 billion, a PE ratio of -4.38 and a beta of 1.61.

Mirati Therapeutics (NASDAQ:MRTX – Get Rating) last announced its earnings results on Wednesday, May 4th. The biotechnology company reported ($3.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.37) by ($0.03). The firm had revenue of $0.71 million during the quarter, compared to analysts’ expectations of $0.18 million. During the same quarter in the previous year, the firm earned ($2.67) EPS. The firm’s revenue was up 6990.0% on a year-over-year basis. Research analysts expect that Mirati Therapeutics will post -14.37 earnings per share for the current fiscal year.

A number of hedge funds have recently modified their holdings of MRTX. Kistler Tiffany Companies LLC bought a new position in shares of Mirati Therapeutics in the fourth quarter worth $28,000. CI Investments Inc. bought a new position in shares of Mirati Therapeutics in the third quarter worth $35,000. Signaturefd LLC increased its holdings in shares of Mirati Therapeutics by 102.4% in the first quarter. Signaturefd LLC now owns 338 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 171 shares during the period. Parallel Advisors LLC increased its holdings in shares of Mirati Therapeutics by 307.7% in the first quarter. Parallel Advisors LLC now owns 371 shares of the biotechnology company’s stock worth $31,000 after purchasing an additional 280 shares during the period. Finally, US Bancorp DE increased its holdings in shares of Mirati Therapeutics by 79.4% in the third quarter. US Bancorp DE now owns 488 shares of the biotechnology company’s stock worth $86,000 after purchasing an additional 216 shares during the period.

About Mirati Therapeutics (Get Rating)

Mirati Therapeutics, Inc, a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development.

Featured Stories